Target intelligence / Profile preview

Sclerostin

Molecular classification: Secreted glycoprotein

Overview

Sclerostin is a secreted glycoprotein that acts as a potent negative regulator of bone formation and plays a central role in bone homeostasis by inhibiting the Wnt/β-catenin signaling pathway, which is crucial for osteoblast function and bone growth.

Other names: SOST

Mechanism of action

Inhibition of Wnt/β-catenin signaling by binding to LRP5/6 co-receptors on osteoblasts, blocking canonical Wnt signaling required for new bone synthesis. Also binds to LRP4, acting as a molecular coordinator of both bone formation and resorption processes.

Biological functions

Negative regulation of bone formationRegulation of Wnt signalingRegulation of bone homeostasis

Disease associations

SclerosteosisVan Buchem diseaseOsteoporosisOsteopenia

Beyond the preview

Go deeper on Sclerostin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sclerostin.

Explore the full profile